Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : This acquisition is a major milestone to build a robust offering of novel, non-opioid treatments to improve patient care along the neural pain pathway while simultaneously providing a complementary commercial asset in ZILRETTA for the treatment of OA kne...
Product Name : Zilretta
Product Type : Hormone
Upfront Cash : Undisclosed
November 10, 2021
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Pacira BioSciences
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group. Clinical data from the first two cohorts indicate that FX201 appears to be generally safe and well-tolerated at the low and mid doses.
Product Name : FX201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort.
Product Name : FX201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : Humantakinogene Hadenovec
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Funapide
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo.
Product Name : FX301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2020
Lead Product(s) : Funapide
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Funapide
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New animal data show FX301 provided sustained, post-operative analgesic effect with no impairment in motor function compared to liposomal bupivacaine and placebo.
Product Name : FX301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Funapide
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hk Tainuo
Deal Size : $42.5 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Flexion will be solely responsible for the manufacture and supply of ZILRETTA to HK Tainuo for all clinical and commercial activities.
Product Name : Zilretta
Product Type : Hormone
Upfront Cash : $10.0 million
January 04, 2020
Lead Product(s) : Triamcinolone Acetonide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hk Tainuo
Deal Size : $42.5 million
Deal Type : Licensing Agreement